share_log

Chimerix | 10-Q: Q2 2024 Earnings Report

Chimerix | 10-Q: Q2 2024 Earnings Report

Chimerix | 10-Q：2024財年二季報
美股SEC公告 ·  2024/08/13 19:27

Moomoo AI 已提取核心訊息

Chimerix reported Q2 2024 revenues of $0.1 million and a net loss of $20.7 million ($0.23 per share), compared to revenues of $26,000 and a net loss of $18.6 million ($0.21 per share) in Q2 2023. Research and development expenses increased to $18.4 million from $16.9 million YoY, while general and administrative expenses remained relatively flat at $4.5 million. The company ended the quarter with $171.5 million in cash and investments.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with interim overall survival data expected in Q3 2025. The trial is enrolling patients across 140 sites in 13 countries. Additionally, Chimerix is pursuing Provisional Registration pathway for dordaviprone in Australia, with potential filing by year-end 2024.The company's second-generation compound ONC206 is progressing through dose escalation trials in CNS tumors, with over 75 patients enrolled to date. On June 27, Chimerix received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement and has until December 24, 2024 to regain compliance.
Chimerix reported Q2 2024 revenues of $0.1 million and a net loss of $20.7 million ($0.23 per share), compared to revenues of $26,000 and a net loss of $18.6 million ($0.21 per share) in Q2 2023. Research and development expenses increased to $18.4 million from $16.9 million YoY, while general and administrative expenses remained relatively flat at $4.5 million. The company ended the quarter with $171.5 million in cash and investments.The company continues to advance its Phase 3 ACTION trial evaluating dordaviprone for H3 K27M-mutant diffuse glioma, with interim overall survival data expected in Q3 2025. The trial is enrolling patients across 140 sites in 13 countries. Additionally, Chimerix is pursuing Provisional Registration pathway for dordaviprone in Australia, with potential filing by year-end 2024.The company's second-generation compound ONC206 is progressing through dose escalation trials in CNS tumors, with over 75 patients enrolled to date. On June 27, Chimerix received notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price requirement and has until December 24, 2024 to regain compliance.
Chimerix報告2024年第二季度收入爲10萬美元，淨虧損爲2070萬美元（每股0.23美元），相比之下，2023年第二季度的收入爲26000美元，淨虧損爲1860萬美元（每股0.21美元）。研發費用同比增長至1840萬美元，較去年1690萬美元有所增加，而一般及行政費用保持相對平穩，爲450萬美元。公司在季度末擁有現金和投資共17150萬美元。公司繼續推進其評估dordaviprone用於H3 K2700萬突變瀰漫性膠質瘤的第三階段ACTION試驗，預計將在2025年第三季度公佈中期整體生存數據。該試驗在13個國家的140個地點招募患者。此外，Chimerix正在澳洲尋求dordavip...展開全部
Chimerix報告2024年第二季度收入爲10萬美元，淨虧損爲2070萬美元（每股0.23美元），相比之下，2023年第二季度的收入爲26000美元，淨虧損爲1860萬美元（每股0.21美元）。研發費用同比增長至1840萬美元，較去年1690萬美元有所增加，而一般及行政費用保持相對平穩，爲450萬美元。公司在季度末擁有現金和投資共17150萬美元。公司繼續推進其評估dordaviprone用於H3 K2700萬突變瀰漫性膠質瘤的第三階段ACTION試驗，預計將在2025年第三季度公佈中期整體生存數據。該試驗在13個國家的140個地點招募患者。此外，Chimerix正在澳洲尋求dordaviprone的臨時註冊途徑，預計將在2024年底前提交申請。公司的第二代化合物ONC206正在通過中樞神經系統腫瘤的劑量遞增試驗，目前已有超過75名患者入組。截至6月27日，Chimerix收到了來自納斯達克的通知，關於未能遵守1.00美元的最低買盤價格要求，並必須在2024年12月24日之前恢復合規。

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

獨立文件5  查看翻譯

獨立文件6  查看翻譯

獨立文件7  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    相關股票 相關股票
    代碼 迷你走勢 最新價
    Portage Biotech
    PRTG
    -- 9.600
    萊斯康製藥
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解鎖完整榜單
    重估中國資產
    繼中國開創性的DeepSeek技術推出之後，華爾街大行重估對中國市場的投資前景。
    熱門討論
    FOMC維持利率但不確定性高企：美股後市走向如何？
    🎙️討論 1. 美聯儲強調政策路徑存在「高度不確定性」，你更關注利率預期變化還是經濟數據對市場的短期影響？ 2. 若核心通脹維持高位，哪類板塊更具交易機會——防禦型股票還是科技成長股？ 展开
    聯邦公開市場委員會新聞發佈會，2025年3月19日